Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?

Already, 2023 is shaping up to be an eventful year in Alzheimer’s disease (AD) drug development. After the FDA’s approval of Eisai/Biogen’s Leqembi (lecanemab) on January 6, the AD field is now looking toward the upcoming approval decision for Lilly’s donanemab expected in May. Although both donanemab and lecanemab have similar therapeutic targets, the two AD antibodies employed notably different trial designs.